Nanobiotix (NBTX) Competitors $5.27 +0.04 (+0.76%) Closing price 07/11/2025 03:30 PM EasternExtended Trading$5.55 +0.28 (+5.33%) As of 07/11/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. LENZ, ZYME, RCUS, AVDL, COGT, OCS, CMRX, CDMO, QURE, and CRMDShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include LENZ Therapeutics (LENZ), Zymeworks (ZYME), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors LENZ Therapeutics Zymeworks Arcus Biosciences Avadel Pharmaceuticals Cogent Biosciences Oculis Chimerix Avid Bioservices uniQure CorMedix LENZ Therapeutics (NASDAQ:LENZ) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends. Is LENZ or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -23.74% -22.65% Nanobiotix N/A N/A N/A Does the media favor LENZ or NBTX? In the previous week, LENZ Therapeutics and LENZ Therapeutics both had 4 articles in the media. Nanobiotix's average media sentiment score of 0.70 beat LENZ Therapeutics' score of 0.38 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, LENZ or NBTX? LENZ Therapeutics has higher earnings, but lower revenue than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.77-19.60Nanobiotix$39.18M6.34-$73.73MN/AN/A Do institutionals and insiders believe in LENZ or NBTX? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, LENZ or NBTX? LENZ Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Do analysts rate LENZ or NBTX? LENZ Therapeutics presently has a consensus price target of $46.60, suggesting a potential upside of 34.33%. Nanobiotix has a consensus price target of $8.00, suggesting a potential upside of 51.80%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryLENZ Therapeutics beats Nanobiotix on 7 of the 12 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$246.51M$2.45B$5.60B$9.11BDividend YieldN/A1.79%5.24%4.02%P/E RatioN/A9.4227.9620.25Price / Sales6.34729.02430.8999.65Price / CashN/A165.3637.4658.16Price / Book-3.494.608.045.49Net Income-$73.73M$31.26M$3.18B$250.27M7 Day Performance5.19%4.80%3.63%4.75%1 Month Performance-8.51%5.42%4.04%7.64%1 Year Performance-7.22%-4.36%29.55%16.34% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix2.7934 of 5 stars$5.27+0.8%$8.00+51.8%-7.1%$246.51M$39.18M0.00100Positive NewsGap UpLENZLENZ Therapeutics1.3524 of 5 stars$31.48-3.2%$46.60+48.0%+76.9%$915.59MN/A-17.79110ZYMEZymeworks2.9032 of 5 stars$13.08+0.3%$21.00+60.6%+35.2%$910.07M$93.38M-8.72460RCUSArcus Biosciences2.1288 of 5 stars$8.23-2.8%$21.29+158.6%-37.3%$896.85M$258M-1.96500News CoverageAVDLAvadel Pharmaceuticals1.9814 of 5 stars$8.89-0.4%$18.17+104.3%-41.5%$863.88M$169.12M-32.9370COGTCogent Biosciences3.0354 of 5 stars$9.35+23.4%$16.33+74.7%+20.1%$863.03MN/A-5.0880Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeOCSOculis2.1969 of 5 stars$18.74-1.4%$35.33+88.5%+58.4%$829.59M$780K-7.102News CoverageCMRXChimerix0.5467 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6156 of 5 stars$12.50+0.1%$12.25-2.0%+56.2%$799.18M$139.91M-5.23320News CoverageHigh Trading VolumeQUREuniQure2.714 of 5 stars$14.31-0.8%$37.82+164.3%+61.6%$789.86M$27.12M-3.26500CRMDCorMedix2.7217 of 5 stars$11.42-1.7%$17.14+50.1%+128.5%$788.13M$82.55M51.9130Positive News Related Companies and Tools Related Companies LENZ Therapeutics Competitors Zymeworks Competitors Arcus Biosciences Competitors Avadel Pharmaceuticals Competitors Cogent Biosciences Competitors Oculis Competitors Chimerix Competitors Avid Bioservices Competitors uniQure Competitors CorMedix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBTX Stock Alerts